IONS
NASDAQ · Biotechnology
Ionis Pharmaceuticals Inc
$38.80
-1.35 (-3.36%)
Financial Highlights (FY 2026)
Revenue
979.90M
Net Income
-396,009,323
Gross Margin
98.3%
Profit Margin
-40.4%
Rev Growth
+17.1%
D/E Ratio
4.77
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 98.3% | 98.3% | 30.8% | 30.8% |
| Operating Margin | -40.4% | -36.4% | -25.1% | -25.9% |
| Profit Margin | -40.4% | -38.4% | -28.4% | -22.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 979.90M | 836.66M | 6.52B | 6.82B |
| Gross Profit | 963.34M | 822.52M | 2.01B | 2.10B |
| Operating Income | -396,368,215 | -304,586,230 | -1,637,174,560 | -1,768,391,203 |
| Net Income | -396,009,323 | -304,310,442 | -1,853,302,223 | -1,556,416,967 |
| Gross Margin | 98.3% | 98.3% | 30.8% | 30.8% |
| Operating Margin | -40.4% | -36.4% | -25.1% | -25.9% |
| Profit Margin | -40.4% | -38.4% | -28.4% | -22.8% |
| Rev Growth | +17.1% | +17.1% | -9.9% | -5.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 2.99B | 2.99B | 4.25B | 4.25B |
| Total Equity | 627.06M | 627.06M | 5.68B | 5.61B |
| D/E Ratio | 4.77 | 4.77 | 0.75 | 0.76 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -385,924,253 | -313,036,236 | -2,518,216,651 | -2,334,638,478 |
| Free Cash Flow | — | — | -1,126,512,375 | -1,241,201,522 |